Ricardo Fernandez retweeted
España prueba un cribado de #CáncerDePróstata dentro del proyecto europeo Praise-U.
En el piloto de Ferrol (12.000 invitaciones), la estrategia PSA→RM→biopsia, muestra menos biopsias y mayor valor predictivo. El 61,5% de las biopsias indicadas detectó cáncer.
Ricardo Fernandez retweeted
Ricardo Fernandez retweeted
Combination lenvatinib-tislelizumab for fumarate hydratase-deficient #RenalCellCarcinoma. Promising results for FH-deficient #RCC! Dr. Wen Kong shares data on #lenvatinib + #tislelizumab in 1L treatment—90% ORR, 20% CRs, and universal tumor shrinkage. Could TKI-IO combos outperform current guidelines? #WatchNow > bit.ly/4kR7uD3 @PBarataMD
Ricardo Fernandez retweeted
The Uromigos 🏊♀️ 🏊♀️ 🏊♂️ team below - the race Alfonso Gomez 🏆 🥇 and is coming to the annual meeting in Nashville 7th/8th November #GUtrends25
Ricardo Fernandez retweeted
Entrega de premios de los talleres y broche final a un gran Curso SOGUG de Cáncer Renal y Tumores Germinales. Nos vamos de Gijón con satisfacción por el nivel cientifico y humano del evento. @sogug1 #SomosSOGUG
Ricardo Fernandez retweeted
Eternamente agradecida a todo el equipo & coautores, no hay mayor suerte que compartir camino con vosotros @EnekoNovo,
@rfr64, Xabier Elcoroaristizabal,
Patricia Ruíz, et al
@upvehu @OSIEECruces Plataforma Genética Genómica @biobizkaia @gonorte_ #ASONMEC
ascopubs.org/doi/10.1200/JCO…
Ricardo Fernandez retweeted
Ricardo Fernandez retweeted
🔊Reunión PostASCO-GU 🔊
🗓️ 20 de febrero
🕒 17h
📍 Online
✍️ events.tacticsmd.net/actuali…
Ricardo Fernandez retweeted
Have you ever heard about SDHB deficient renal cell carcinoma 🕵️♂️?
SDHB-deficient kidney cancer is a rare but highly aggressive tumor, often striking patients at a younger age—typically in their 30s and 40s. 🧬 Linked to hereditary mutations in the SDHB gene, it carries a poor prognosis with higher mortality rates compared to other kidney cancers. It’s time to raise awareness and advocate for early detection and genetic screening! 💪
#SDHB #KidneyCancer #Genetics #HereditaryCancer #CancerResearch #Health #MedicalScience #CancerAwareness #GeneticTesting
@AmerUrological, @Uroweb, @ASCO, @PathSoc. #Uropathology #urothelial #cancer #MedicalInnovation @NEJM @JAMANetwork @JAMA_current @OncoAlert @onkowissen @imedverse @Histo_Journal @niklas_kluemper #pathtwitter
@brookmans76 @PGrivasMDPhD @DrYukselUrun @shilpaonc @drenriquegrande @amerseburger @FaltasLab
Ricardo Fernandez retweeted
Up to 82% of pregnant surgeons experience miscarriage, preterm delivery, and intrauterine growth restriction. Occupational hazards, including prolonged standing, physical exertion, overnight shifts, and teratogenic exposure, contribute to these risks.
ja.ma/4eUXVQn
Ricardo Fernandez retweeted
📣@whallradonc presents phase II trial of dose escalated RT and elective nodes in VERY high risk #prostatecancer.
➡️10-year med. F/U
➡️>25% risk of clinical nodal involvement.
➡️outstanding 96% 10-year freedom from distant Mets
💥Hallelujah!
#pcsm #ASTRO24
Ricardo Fernandez retweeted
Results from the SWOG S1314 trial validate earlier findings in ATM, RB1, ERCC2, or FANCC predict CR to NAC in muscle-invasive bladder cancer.. not perfect but predictive .. with NPV 86% .. better at predicting presence of disease > absence sciencedirect.com/science/ar… @EUplatinum
Ricardo Fernandez retweeted
📰 Updated IF for Oncology/Hematology journals
Updated 2023 impact factor list for hematology/oncology journals
Interesting to see the post-COVID reductions as we get closer to normal
(Will add the few I'm missing when I get them) #medtwitter #hematology #IF #impactfactor
Ricardo Fernandez retweeted
The IBCG Quick Guide to Non-Muscle Invasive Bladder Cancer (NMIBC)
Bladder Cancer Quick Reference Sheet summarizes essential details on diagnosis, treatment options, and follow-up for NMIBC all in one convenient place #AUA24 #EAU24 #IBCG24 #ASCO24
Designed by @AmandaMyersMD #OncSurgery @MDAndersonNews
@PGrivasMDPhD @shilpaonc @UrogerliMD @SimaPorten @pjhensley11 @SWilliams_MD
Ricardo Fernandez retweeted
Latest Results for Javelin 100 bladder trial from @ASCO #ASCO24
Avelumab maintenance trial data for pts with low tumor burden.
For Non Viseral Metastasis-
Median OS -31.4 months -HR- 0.60
For LN only Disease-
Median OS 31.9 months ❣- HR - 0.86
For Pelvic and Retroperitoneal LN only Disease-
Median OS -31.2 months- HR - 0.72
This is inspite of close to 75 % pts on control arm receiving post progression anti cancer therapy .
Great Data 👍 @OncoAlert @OncBrothers @Larvol
Ricardo Fernandez retweeted
Genes that should be included in germline testing panels by tumor type (including prostate cancer): ASCO guideline just published.
ascopubs.org/doi/pdf/10.1200…
Ricardo Fernandez retweeted
Interesante lectura
Artículo de @XavierMarcet
LIDERAZGOS SENCILLOS
Liderar es influir más que mandar. Admiro a los líderes que hacen que parezca fácil. Sin sobreactuar. Alcanzando la sencillez.
Hoy, en @LaVanguardia


















































